Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)

Completed · Phase 2

Conditions studied: Alopecia Universalis (AU), Alopecia Totalis (AT)

In brief

The primary objective is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-50002 Topical Solution compared to vehicle in subjects with AU and AT.

Key facts

Study ID
NCT03315689
Run by
Aclaris Therapeutics, Inc.
People needed
11
Starts
2017-12-14
Expected to finish
2019-06-20
Last updated by the study team
2020-07-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.